



Marksans Pharma Ltd.

Date: 12th October, 2022

BSE Limited

Corporate Relation Department
PhirozeJeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Ref: Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Further to our letter dated 11th October, 2022 in connection with the Company's Press Release & pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby provide below information on capacity addition:

1	Existing Capacity	8 Billion units per annum
2	Existing Capacity Utilization	6 Billion units per annum (75%)
3	Proposed Capacity Addition	8 Billion units per annum
4	Period within which the proposed capacity is to be added	2 Years
5	Investment required	Rs. 200 Crore
6	Mode of financing	Equity and Internal Accrual
7	Rationale	The acquisition has potential to significantly expand Company's manufacturing capability and accelerate core growth strategy. It will supplement innovative product portfolio, as the Company plans to begin manufacturing of creams, ointments, etc. in India. It is also a testament to Company's commitment to invest in product innovation, expand capacities, and drive market share gains. We are confident that this acquisition will lead to transformational growth journey unlocking further value for Company's shareholders.

You are requested to note the above in your records.

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com
www.marksanspharma.com